Selection of breast cancer patients for an aromatase inhibitor after radiation and tamoxifen

被引：0
|
作者：
Freedman, GM [1 ]
Anderson, P [1 ]
Li, T [1 ]
Ross, E [1 ]
Swaby, R [1 ]
Goldstein, L [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [41] Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
    Weeraman, S.
    Hunsley, C.
    Wall, M.
    Kirby, R.
    BREAST CANCER RESEARCH, 2010, 12 : S14 - S14
  • [42] Tamoxifen versus aromatase inhibitors for breast cancer prevention
    Yue, W
    Wang, JP
    Li, YB
    Bocchinfuso, WP
    Korach, KS
    Devanesan, PD
    Rogan, E
    Cavalieri, E
    Santen, RJ
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 925S - 930S
  • [43] Tamoxifen or aromatase inhibitors in breast cancer : Efficacy and safety
    Neven, P.
    Van den Broecke, R.
    ACTA CHIRURGICA BELGICA, 2007, 107 (03) : 240 - 256
  • [44] Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a 'Switching' Policy in Postmenopausal Patients after Initial Tamoxifen
    Geffen, D. B.
    Tokar, M.
    Abu-Ghanem, S.
    Braunstein, R.
    Koretz, M.
    Amir, N.
    Delgado, B.
    Sion-Vardi, N.
    Ariad, S.
    Lazarev, I.
    ONCOLOGY, 2013, 85 (03) : 145 - 152
  • [45] Vorozole (Rivizor™):: an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure
    Paridaens, R
    Roy, JA
    Nooij, M
    Klijn, J
    Houston, SJ
    Beex, LVAM
    Vinholes, J
    Tomiak, E
    Van Vreckem, A
    Langenaeken, C
    Van Glabbeke, M
    Piccart, MJ
    ANTI-CANCER DRUGS, 1998, 9 (01) : 29 - 35
  • [46] Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity
    R. T. Chlebowski
    R. Haque
    H. Hedlin
    N. Col
    E. Paskett
    J. E. Manson
    J. T. Kubo
    K. C. Johnson
    J. Wactawski-Wende
    K. Pan
    G. Anderson
    Breast Cancer Research and Treatment, 2015, 154 : 609 - 616
  • [47] Changes in an artificial intelligence model score for breast cancer detection (Transpara) with tamoxifen and aromatase inhibitor treatment
    Wang, Yvonne
    Scott, Christopher
    Jensen, Matthew
    Hursh, Dan
    Brandt, Kathleen
    Norman, Aaron
    Wu, Fang Fang
    Winham, Stacey
    Kerlikowske, Karla
    Vachon, Celine
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Benefit/risk of invasive breast cancer adjuvant tamoxifen or aromatase inhibitor use by age, racelethnicity, and comorbidity
    Chlebowski, R. T.
    Haque, R.
    Col, N.
    Paskett, E.
    Manson, J. E.
    Kubo, J. T.
    Johnson, K. C.
    Wactawski-Wende, J.
    Anderson, G.
    CANCER RESEARCH, 2013, 73
  • [49] Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO.
    Haque, R.
    Schottinger, J. E.
    Fisher, A. H.
    Shi, J. M.
    Avila, C. C.
    Guo, A.
    Zelt, S.
    Quinn, V. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology
    Morales, Leilani
    Paridaens, Robert
    Timmerman, Dirk
    Neven, Patrick
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5603 - 5603
12345